FDA Update

Clinical Laboratory Improvement Advisory Committee Meeting September 5, 2007

Alberto Gutierrez

Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health US Food and Drug Administration





- Organizational Changes
- FDA Guidance Update
- User Fee Update
- Pre-Market Update
- Post-Market Update



Organizational Changes

- New Center Deputy Director
 Mark Raza
- New Office Deputy Director
 Alberto Gutierrez
- New/Old Division Director for Chemistry and Toxicology
 - Jean Cooper
- Return of Liz Mansfield as Senior Policy Advisor



• IVDMIA

- → First Draft Published Sept. 2006
- → 180 Day Comment Period
- \rightarrow Public meeting to discuss issues
- → Second Draft Published July 2006

• ASR

- → First Draft Published Sept. 2006
- → 180 Day Comment Period



- Assayed and Unassayed Quality Control Material
- Pharmacogenetic Tests and Genetic Tests for Heritable Markers
- Review Criteria for Assessment of Qualitative Fecal Occult Blood In Vitro Diagnostic Devices
- In Vitro Diagnostic Devices to Detect Influenza A Viruses: Labeling and Regulatory Path



Class II Special Controls

- Gene Expression Profiling Test System for Breast Cancer Prognosis
- Antimicrobial Susceptibility Test (AST) Systems
- Herpes Simplex Virus Types 1 and 2 Serological Assays



• CLIA Waiver Guidance – Working its way through the system.



User Fee Update

• MDUFMA II

- →Specific OIVD Goals
 - o Guidance Commitments
 - o Performance Goals for CLIA Waiver Petitions
 - o Pilot Study for Co-review of PMA/510(k) and CLIA Waiver
 - o Re-classification of Class II and Class I devices
 - o Clear Path for Review of Molecular Diagnostic Tests



Pre-Market Update

- Veridex Metastatic Breast Cancer
- Binax NOW Malaria
- 7 Day Continuous Glucose Sensor



Post-Market Update

- Post-Market Transformation
- Lab Net

→ Few Signals but significant identified
 → OIVD actively calling the laboratories that have joined